Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 341

1.

Revisiting the role of ABC transporters in multidrug-resistant cancer.

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM.

Nat Rev Cancer. 2018 Jul;18(7):452-464. doi: 10.1038/s41568-018-0005-8. Review.

PMID:
29643473
2.

Variation in the management of SSRI-exposed babies across England.

Thomas E, Peacock PJ, Bates SE.

BMJ Paediatr Open. 2017 Aug 11;1(1):e000060. doi: 10.1136/bmjpo-2017-000060. eCollection 2017.

3.

Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.

Zhang GN, Zhang YK, Wang YJ, Gupta P, Ashby CR Jr, Alqahtani S, Deng T, Bates SE, Kaddoumi A, Wurpel JND, Lei YX, Chen ZS.

Cancer Lett. 2018 Jun 28;424:19-29. doi: 10.1016/j.canlet.2018.02.040. Epub 2018 Mar 5.

PMID:
29518481
4.

Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Jun;29(5):457-465. doi: 10.1097/CAD.0000000000000596.

PMID:
29420340
5.

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.

Tang SW, Thomas A, Murai J, Trepel JB, Bates SE, Rajapakse VN, Pommier Y.

Clin Cancer Res. 2018 Apr 15;24(8):1944-1953. doi: 10.1158/1078-0432.CCR-17-0443. Epub 2018 Feb 1.

PMID:
29391350
6.

Mutation Analysis in Cultured Cells of Transgenic Rodents.

Besaratinia A, Zheng A, Bates SE, Tommasi S.

Int J Mol Sci. 2018 Jan 16;19(1). pii: E262. doi: 10.3390/ijms19010262. Review.

7.

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, Yuno A, Lee S, Zhang Y, Tran L, Yutzy W, Rajan A, Guha U, Chen H, Hassan R, Alewine CC, Szabo E, Bates SE, Kinders RJ, Steinberg SM, Doroshow JH, Aladjem MI, Trepel JB, Pommier Y.

J Clin Oncol. 2018 Jun 1;36(16):1594-1602. doi: 10.1200/JCO.2017.76.6915. Epub 2017 Dec 18.

PMID:
29252124
8.

Metabolic symbiosis in cancer and its therapeutic implication.

Lipstein MR, Pal I, Bates SE, Deng C.

Semin Oncol. 2017 Jun;44(3):233-234. doi: 10.1053/j.seminoncol.2017.09.001. Epub 2017 Oct 10. No abstract available.

PMID:
29248135
9.

Limited mutagenicity of electronic cigarettes in mouse or human cells in vitro.

Tommasi S, Bates SE, Behar RZ, Talbot P, Besaratinia A.

Lung Cancer. 2017 Oct;112:41-46. doi: 10.1016/j.lungcan.2017.07.035. Epub 2017 Aug 3.

PMID:
29191599
10.

Current challenges in the management of breast cancer brain metastases.

O'Sullivan CC, Davarpanah NN, Abraham J, Bates SE.

Semin Oncol. 2017 Apr;44(2):85-100. doi: 10.1053/j.seminoncol.2017.06.006. Epub 2017 Jul 8. Review.

PMID:
28923217
11.

Refining Immunotherapy Approvals.

Bates SE.

Clin Cancer Res. 2017 Sep 1;23(17):4948-4949. doi: 10.1158/1078-0432.CCR-17-2025. No abstract available.

PMID:
28864722
12.

Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.

Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S.

Leuk Lymphoma. 2018 Apr;59(4):880-887. doi: 10.1080/10428194.2017.1361022. Epub 2017 Aug 30.

PMID:
28853310
13.

Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels.

Mlejnek P, Kosztyu P, Dolezel P, Bates SE, Ruzickova E.

Chem Biol Interact. 2017 Aug 1;273:171-179. doi: 10.1016/j.cbi.2017.06.012. Epub 2017 Jun 13.

PMID:
28623111
14.

Base Pairs to Populations.

Bates SE.

Clin Cancer Res. 2017 Jun 1;23(11):2610. doi: 10.1158/1078-0432.CCR-16-2631. No abstract available.

15.

Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma".

Borazanci E, Dang CV, Robey RW, Bates SE, Chabot JA, Von Hoff DD.

Clin Cancer Res. 2017 Apr 1;23(7):1629-1637. doi: 10.1158/1078-0432.CCR-16-2070. Review.

16.

Pancreatic Cancer: Challenge and Inspiration.

Bates SE.

Clin Cancer Res. 2017 Apr 1;23(7):1628. doi: 10.1158/1078-0432.CCR-16-2069. No abstract available.

17.

Too Many Journals.

Bates SE.

Oncologist. 2017 Feb;22(2):126-128. doi: 10.1634/theoncologist.2017-0012. Epub 2017 Feb 10. No abstract available.

18.

Multiple Myeloma: Multiplying Therapies.

Bates SE.

Clin Cancer Res. 2016 Nov 15;22(22):5418. doi: 10.1158/1078-0432.CCR-16-0624. No abstract available.

19.

DNA Advanced Glycation End Products (DNA-AGEs) Are Elevated in Urine and Tissue in an Animal Model of Type 2 Diabetes.

Jaramillo R, Shuck SC, Chan YS, Liu X, Bates SE, Lim PP, Tamae D, Lacoste S, O'Connor TR, Termini J.

Chem Res Toxicol. 2017 Feb 20;30(2):689-698. doi: 10.1021/acs.chemrestox.6b00414. Epub 2017 Feb 3.

20.

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R, Murphy M, Morrell J, Beetsch J, Sargent DJ, Scher HI, Lebowitz P, Simon R, Stein WD, Bates SE, Fojo T.

Lancet Oncol. 2017 Jan;18(1):143-154. doi: 10.1016/S1470-2045(16)30633-7. Epub 2016 Dec 13.

PMID:
27979599
21.

Resuscitation of the Newborn: Simulating for Confidence.

Peacock PJ, Woodman A, McCay W, Bates SE.

Cureus. 2016 Sep 20;8(9):e790.

22.

Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters.

Payabyab EC, Balasubramaniam S, Edgerly M, Velarde M, Merino MJ, Venkatesan AM, Leuva H, Litman T, Bates SE, Fojo T.

Clin Cancer Res. 2016 Oct 15;22(20):4989-5000.

23.

Endocrine Cancers: Defying the Paradigms.

Bates SE.

Clin Cancer Res. 2016 Oct 15;22(20):4980. No abstract available.

24.

Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.

Bahr JC, Robey RW, Luchenko V, Basseville A, Chakraborty AR, Kozlowski H, Pauly GT, Patel P, Schneider JP, Gottesman MM, Bates SE.

Oncotarget. 2016 Oct 25;7(43):69804-69815. doi: 10.18632/oncotarget.12001.

25.

ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment.

O'Sullivan CC, Lindenberg M, Bryla C, Patronas N, Peer CJ, Amiri-Kordestani L, Davarpanah N, Gonzalez EM, Burotto M, Choyke P, Steinberg SM, Liewehr DJ, Figg WD, Fojo T, Balasubramaniam S, Bates SE.

Breast Cancer Res Treat. 2016 Nov;160(1):51-59. Epub 2016 Sep 12.

PMID:
27620882
26.

Phase I Testing: 60 Years in the Making.

Bates SE.

Clin Cancer Res. 2016 Jun 1;22(11):2612. doi: 10.1158/1078-0432.CCR-15-2642. No abstract available.

27.

Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer.

O'Sullivan CC, Bates SE.

Oncologist. 2016 May;21(5):523-6. doi: 10.1634/theoncologist.2016-0108. Epub 2016 Apr 22. No abstract available.

28.

Disruptive Immunology.

Bates SE.

Clin Cancer Res. 2016 Apr 15;22(8):1844. doi: 10.1158/1078-0432.CCR-15-1850. No abstract available.

29.

Romidepsin Therapy Over 5 Years in a Clinical Setting-Real-world Experience.

Bates SE, Geskin LJ.

JAMA Oncol. 2016 Jun 1;2(6):794-5. doi: 10.1001/jamaoncol.2016.0072. No abstract available.

PMID:
27054784
30.

Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.

Bates SE, Fojo T.

Nat Rev Clin Oncol. 2016 Apr;13(4):205-6. doi: 10.1038/nrclinonc.2016.22. Epub 2016 Feb 23. No abstract available.

PMID:
26902963
31.

Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.

Massey PR, Wang R, Prasad V, Bates SE, Fojo T.

Oncologist. 2016 Mar;21(3):261-8. doi: 10.1634/theoncologist.2015-0516. Epub 2016 Feb 17.

32.

The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.

Macalou S, Robey RW, Jabor Gozzi G, Shukla S, Grosjean I, Hegedus T, Ambudkar SV, Bates SE, Di Pietro A.

Cell Mol Life Sci. 2016 May;73(9):1927-37. doi: 10.1007/s00018-015-2118-5. Epub 2015 Dec 26.

PMID:
26708291
33.

UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.

Peer CJ, Goey AK, Sissung TM, Erlich S, Lee MJ, Tomita Y, Trepel JB, Piekarz R, Balasubramaniam S, Bates SE, Figg WD.

J Clin Pharmacol. 2016 Apr;56(4):450-60. doi: 10.1002/jcph.627. Epub 2015 Dec 4.

PMID:
26637161
34.

How Do Cancer Cells Die?

Bates SE.

Clin Cancer Res. 2015 Nov 15;21(22):5014. doi: 10.1158/1078-0432.CCR-15-1203. No abstract available.

35.

Advancing Clinical Trials to Streamline Drug Development.

Bates SE, Berry DA, Balasubramaniam S, Bailey S, LoRusso PM, Rubin EH.

Clin Cancer Res. 2015 Oct 15;21(20):4527-35. doi: 10.1158/1078-0432.CCR-15-0039.

36.

On Innovating and Inspiring the Clinical Trial Enterprise.

Bates SE.

Clin Cancer Res. 2015 Oct 15;21(20):4526. doi: 10.1158/1078-0432.CCR-15-0038. No abstract available.

37.

Assessing Adolescent Substance Abuse Programs with Updated Quality Indicators: The Development of a Consumer Guide for Adolescent Treatment.

Cacciola JS, Meyers K, Bates SE, Rosenwasser B, Arria A, McLellan AT.

J Child Adolesc Subst Abuse. 2015;24(3):142-154. Epub 2015 Mar 6.

38.

Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis.

Fatima N, Cohen DC, Sukumar G, Sissung TM, Schooley JF Jr, Haigney MC, Claycomb WC, Cox RT, Dalgard CL, Bates SE, Flagg TP.

Front Pharmacol. 2015 Aug 13;6:168. doi: 10.3389/fphar.2015.00168. eCollection 2015.

39.

Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.

Goey AK, Sissung TM, Peer CJ, Trepel JB, Lee MJ, Tomita Y, Ehrlich S, Bryla C, Balasubramaniam S, Piekarz R, Steinberg SM, Bates SE, Figg WD.

J Clin Pharmacol. 2016 Apr;56(4):461-73. doi: 10.1002/jcph.625. Epub 2015 Nov 9.

PMID:
26313268
40.

Quit early, quit often.

Bates SE.

Clin Cancer Res. 2015 May 15;21(10):2212. doi: 10.1158/1078-0432.CCR-14-2749. No abstract available.

41.

CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio.

Bates SE, Robey RW, Piekarz RL.

Clin Cancer Res. 2015 May 15;21(10):2195-7. doi: 10.1158/1078-0432.CCR-14-2555.

42.

Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.

Bates SE, Eisch R, Ling A, Rosing D, Turner M, Pittaluga S, Prince HM, Kirschbaum MH, Allen SL, Zain J, Geskin LJ, Joske D, Popplewell L, Cowen EW, Jaffe ES, Nichols J, Kennedy S, Steinberg SM, Liewehr DJ, Showe LC, Steakley C, Wright J, Fojo T, Litman T, Piekarz RL.

Br J Haematol. 2015 Jul;170(1):96-109. doi: 10.1111/bjh.13400. Epub 2015 Apr 19.

43.

Targeting RAS: The Elusive Prize.

Bates SE.

Clin Cancer Res. 2015 Apr 15;21(8):1796. doi: 10.1158/1078-0432.CCR-14-2664. No abstract available.

44.

Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.

Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O'Connor OA.

Clin Cancer Res. 2015 May 1;21(9):2096-106. doi: 10.1158/1078-0432.CCR-14-2249. Epub 2015 Feb 12.

45.

Central nervous system metastasis from breast cancer.

Bates SE.

Oncologist. 2015 Jan;20(1):3-4. doi: 10.1634/theoncologist.2014-0469. Epub 2014 Dec 26. No abstract available.

46.

A phase i study of DMS612, a novel bifunctional alkylating agent.

Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.

Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2.

47.

Central nervous system malignancies: what next?

Bates SE.

Clin Cancer Res. 2014 Nov 15;20(22):5590. doi: 10.1158/1078-0432.CCR-14-1258. No abstract available.

48.

Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice.

O'Connor OA, Bhagat G, Ganapathi K, Pedersen MB, D'Amore F, Radeski D, Bates SE.

Clin Cancer Res. 2014 Oct 15;20(20):5240-54. doi: 10.1158/1078-0432.CCR-14-2020. Review.

49.

The lymphoma medicine cabinet.

Bates SE.

Clin Cancer Res. 2014 Oct 15;20(20):5172. doi: 10.1158/1078-0432.CCR-14-1257. No abstract available.

50.

Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers.

Blagoev KB, Wilkerson J, Stein WD, Yang J, Bates SE, Fojo T.

Cancer Res. 2014 Sep 1;74(17):4653-62. doi: 10.1158/0008-5472.CAN-14-0420.

Supplemental Content

Loading ...
Support Center